Abstract
This phase I trial studies the side effects and best dose of APX005M in treating younger
patients with primary malignant central nervous system tumor that is growing, spreading, or
getting worse (progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can
trigger activation of B cells, monocytes, and dendritic cells and stimulat cytokine release
from lymphocytes and monocytes. APX005M can mediate a direct cytotoxic effect on CD40+ tumor
cells.
